Skip to content
ClinCalc Pro
Menu
IV glucose solution (hypoglycaemia treatment)

Dextrose 10% IV

Brand names: Glucose 10% Infusion

Dextrose 10% IV is an intravenous glucose solution used in the emergency correction of hypoglycaemia, particularly in neonates, children and where concentrated glucose is undesirable, and as a glucose-providing fluid.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It supplies glucose directly to the circulation, rapidly raising blood glucose concentration and providing a metabolic substrate for the brain and other tissues.

Prescribing in practice

  • Confirm hypoglycaemia and re-check capillary or laboratory glucose after administration, as recurrence is common and ongoing infusion or feeding may be required.
  • It is hyperosmolar relative to plasma and can cause thrombophlebitis and extravasation injury, so secure venous access and inspect the cannula site.
  • In suspected alcohol dependence or malnutrition, give thiamine to reduce the risk of precipitating Wernicke's encephalopathy.

Monitoring

Monitor blood glucose closely after administration, together with the infusion site, fluid balance and electrolytes during prolonged use.

Counselling the patient

  • We are giving you sugar directly into a vein to correct a low blood sugar.
  • Tell us if you feel pain or burning at the drip site.
  • Once you are stable we will look at why the blood sugar fell and how to prevent it.

Evidence & guidelines

Intravenous glucose for hypoglycaemia is standard practice supported by UK resuscitation and diabetes emergency guidance.

Reference: JBDS Guidelines; NICE NG3 Neonatal Hypoglycaemia; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

📚 MRCEM Revision

Featured in these MRCEM clinical pathways

Dextrose 10% IV is a core drug in the following exam-focused workups on our sister siteReviseMRCEM.

MRCEM Primary / Intermediate / OSCE candidates: each pathway includes exam-style questions, RCEM/NICE citations, and FAQ summaries.